Integra LifeSciences (NASDAQ:IART) Sees Unusually-High Trading Volume

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) shares saw strong trading volume on Tuesday . 439,018 shares traded hands during trading, a decline of 43% from the previous session's volume of 765,387 shares.The stock last traded at $23.29 and had previously closed at $23.14.

Wall Street Analysts Forecast Growth

IART has been the topic of a number of analyst reports. JMP Securities cut their price target on Integra LifeSciences from $49.00 to $40.00 and set a "market outperform" rating on the stock in a research note on Tuesday. Oppenheimer cut Integra LifeSciences from an "outperform" rating to a "market perform" rating in a research note on Tuesday. StockNews.com lowered shares of Integra LifeSciences from a "buy" rating to a "hold" rating in a research note on Tuesday, April 30th. Citigroup raised shares of Integra LifeSciences from a "sell" rating to a "neutral" rating and set a $38.00 price objective on the stock in a report on Wednesday, April 3rd. Finally, Truist Financial dropped their target price on shares of Integra LifeSciences from $37.00 to $25.00 and set a "hold" rating on the stock in a research report on Tuesday. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Integra LifeSciences presently has an average rating of "Hold" and an average target price of $36.80.

Integra LifeSciences Stock Performance

The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of 29.94, a PEG ratio of 0.87 and a beta of 1.17. The stock's 50 day moving average is $33.33 and its two-hundred day moving average is $38.33.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share for the quarter, hitting the consensus estimate of $0.55. The business had revenue of $368.90 million during the quarter, compared to the consensus estimate of $361.96 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business's quarterly revenue was down 3.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.74 earnings per share. Analysts anticipate that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Arizona State Retirement System lifted its stake in shares of Integra LifeSciences by 1.3% in the 3rd quarter. Arizona State Retirement System now owns 20,988 shares of the life sciences company's stock worth $802,000 after acquiring an additional 279 shares during the period. Cardinal Capital Management raised its holdings in Integra LifeSciences by 1.6% during the fourth quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company's stock worth $962,000 after purchasing an additional 347 shares in the last quarter. Hexagon Capital Partners LLC lifted its position in Integra LifeSciences by 123.3% in the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company's stock valued at $29,000 after purchasing an additional 370 shares during the period. Inspire Investing LLC boosted its holdings in Integra LifeSciences by 5.1% in the 3rd quarter. Inspire Investing LLC now owns 8,004 shares of the life sciences company's stock valued at $306,000 after purchasing an additional 392 shares in the last quarter. Finally, State of Michigan Retirement System increased its position in Integra LifeSciences by 2.5% during the 1st quarter. State of Michigan Retirement System now owns 16,690 shares of the life sciences company's stock worth $592,000 after purchasing an additional 400 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.